Treatments on the map.

Standard-of-care and pipeline products. Open a diagnosis page for setting-by-setting care versus pipeline.

Treatment · withdrawn
Aducanumab
Aducanumab was an amyloid antibody whose US Alzheimer’s indication was later withdrawn. It is historical context, not a current option.
Treatment · approved
Brexpiprazole
Brexpiprazole has a US indication for agitation in Alzheimer’s dementia after other causes are considered. Antipsychotics increase mortality in elderly people with dementia-related psychosis.
Treatment · approved
Donanemab
Donanemab is a monthly infused antibody for early Alzheimer’s disease after amyloid confirmation, with the same ARIA monitoring theme as other amyloid antibodies.
Treatment · approved
Donepezil
Donepezil is a tablet used for cognitive symptoms in Alzheimer’s disease. It may help some people a little. It does not slow the disease itself.
Treatment · approved
Galantamine
Galantamine is a tablet for mild-to-moderate dementia of the Alzheimer’s type. It is not approved for vascular, frontotemporal, or Lewy body dementia.
Treatment · approved
Lecanemab
Lecanemab is an infused antibody for early Alzheimer’s disease after amyloid is confirmed. It can cause brain swelling or bleeding on MRI and is not a cure.
Treatment · approved
Memantine
Memantine is a tablet used in moderate-to-severe dementia of the Alzheimer’s type. It is a symptom treatment, sometimes combined with a cholinesterase inhibitor.
Treatment · phase-3
Remternetug
Remternetug is an investigational amyloid antibody. It is not approved. Trial eligibility is not a treatment recommendation.
Treatment · approved
Rivastigmine
Rivastigmine is used for Alzheimer’s dementia and has a US indication for dementia associated with Parkinson’s disease. It is a symptom treatment.